> CONTAINS NUM EV (CDXX143, 1 U Units = EV (MBq, $99SUP159, UCUM, “MBq”) Measured Activity”) >> HAS OBS CODE EV (CDXX36, 1 U DCID CXXX3 $99SUP159, CONTEXT of “Source Activity Measurement”) >> HAS OBS INCLUDE DTID (1002) 1-n U Observer CONTEXT Context 2 >> HAS OBS DATETME EV (CDXX35, 1 U $99SUP159, CONTEXT “Measured Activity Date Time”) 2 > CONTAINS INCLUDE DTID (XXXX7) 1 M Administration Patient Characteristics 2 > CONTAINS INCLUDE DTID (XXXX5) 1 U Administration Organ Data 2 > CONTAINS CODE EV (121147, 1-n U local billing codes DCM, “Billing Code”) 2 > CONTAINS INCLUDE DTID (XXX11) 1 M Product Administration Data 2 > CONTAINS TEXT EV (121106, 1 U DCM, “Comment”) Content Item Descriptions Row 3 Unique identification of a single radiopharmaceutical administration event. Row 5 The estimated percentage of administered activity lost at the injection site. The estimation includes extravasation, paravenous administration and leakage at the injection site. Row 6 The time the radiopharmaceutical was administered to the patient for imaging purposes.
> CONTAINS NUM EV (CDXX143, $99SUP159, Measured Activity”) 1 U Units = EV (MBq, UCUM, “MBq”) >> HAS OBS CONTEXT CODE EV (CDXX36, $99SUP159, “Source of Activity Measurement”) 1 U DCID CXXX3 >> HAS OBS CONTEXT INCLUDE DTID (1002) Observer Context 1-n U 2 >> HAS OBS CONTEXT DATETME EV (CDXX35, $99SUP159, “Measured Activity Date Time”) 1 U 2 > CONTAINS INCLUDE DTID (XXXX7) Administration Patient Characteristics 1 M 2 > CONTAINS INCLUDE DTID (XXXX5) Administration Organ Data 1 U 2 > CONTAINS CODE EV (121147, DCM, “Billing Code”) 1-n U local billing codes 2 > CONTAINS INCLUDE DTID (XXX11) Product Administration Data 1 M 2 > CONTAINS TEXT EV (121106, DCM, “Comment”) 1 U Content Item Descriptions Row 3 Unique identification of a single radiopharmaceutical administration event. Row 5 The estimated percentage of administered activity lost at the injection site. The estimation includes extravasation, paravenous administration and leakage at the injection site. Row 6 The time the radiopharmaceutical was administered to the patient for imaging purposes.
sup159_lb2.docx